ASP2905|cas:792184-90-8|西域试剂

ASP2905,99.77%

产品编号：Bellancom-122015| CAS NO：792184-90-8| 分子式：C₂₀H₁₇FN₈| 分子量：388.40

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-122015	￥800.00	杭州北京（现货）
Bellancom-122015	￥1300.00	杭州北京（现货）
Bellancom-122015	￥2500.00	杭州北京（现货）
Bellancom-122015	￥4000.00	杭州北京（现货）
Bellancom-122015	￥6500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

ASP2905

产品介绍

ASP2905 是由 Kcnh3/BEC1 基因编码的有效且选择性的钾通道 Kv12.2 抑制剂。ASP2905 可以穿越血脑屏障并具有抗精神病活性。

生物活性

ASP2905 is a potent and selective potassium channel Kv12.2 inhibitor encoded by the Kcnh3/BEC1 gene. ASP2905 can cross the blood-brain barrier and has antipsychotic activities.

体外研究

ASP2905 potently inhibits potassium currents in CHO cells expressing KCNH3 (IC₅₀ of 9.0 nM). ASP2905 (≤10 μM) minimally bound with low affinities to 55 transmembrane proteins. ASP2905 (0.1 µM, 1 µM) decreases the frequency of spontaneous inhibitory postsynaptic currents in cultured rat hippocampal neurons.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

ASP2905 treatment inhibits hyperlocomotion induced by Phencyclidine. And significantly ameliorates Phencyclidine-induced prolongation of immobility time in mice subjected to the forced swimming test.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male ddY mice (aged 4-5 weeks) injected with Phencyclidine hydrochloride (PCP)
Dosage:	0.01 mg/kg, 0.03 mg/kg, 0.1 mg/kg, 0.3 mg/kg
Administration:	Oral administration; once
Result:	Inhibited hyperlocomotion induced by Phencyclidine.

体内研究

ASP2905 treatment inhibits hyperlocomotion induced by Phencyclidine. And significantly ameliorates Phencyclidine-induced prolongation of immobility time in mice subjected to the forced swimming test.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male ddY mice (aged 4-5 weeks) injected with Phencyclidine hydrochloride (PCP)
Dosage:	0.01 mg/kg, 0.03 mg/kg, 0.1 mg/kg, 0.3 mg/kg
Administration:	Oral administration; once
Result:	Inhibited hyperlocomotion induced by Phencyclidine.

性状

Solid

溶解性数据

In Vitro:

DMSO : 100 mg/mL (257.47 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.5747 mL	12.8733 mL	25.7467 mL
5 mM	0.5149 mL	2.5747 mL	5.1493 mL
10 mM	0.2575 mL	1.2873 mL	2.5747 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.5 mg/mL (6.44 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (6.44 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.5 mg/mL (6.44 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (6.44 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。